Last 12 months
Inside the activity.
0 purchase rows · 29 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 9 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2019 Filed Jun 17, 2019 20:35 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Exercise / conversionCommon Stock | 73,005 | $52.17 | $3,808,305.83 |
DisclosureSEC source: 0001022079-19-000147 · wf-form4_156080369748155.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:38 UTC |
STANZIONE DANIELDirector
|
GrantCommon Stock | 1,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000136 · wf-form4_155803907050572.xml · nonDerivative · entry 1 STANZIONE DANIEL · CIK 0001221534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,041 F1 · security: Represents an award of restricted share units. Read SEC document |
| May 14, 2019 Filed May 16, 2019 16:38 UTC |
WILENSKY GAIL RDirector
|
GrantCommon Stock | 1,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000137 · wf-form4_155803912282309.xml · nonDerivative · entry 1 WILENSKY GAIL R · CIK 0001018538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,951 F1 · security: Represents an award of restricted stock units. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:42 UTC |
PFEIFFER GARY MDirector
|
GrantCommon Stock | 1,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000140 · wf-form4_155803930519861.xml · nonDerivative · entry 1 PFEIFFER GARY M · CIK 0001127304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,563 F1 · security: Represents an award of restricted stock units. F2 · balance_after: The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4 pursuant to the Amended and Restated Deferred Compensation Plan for Directors. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:40 UTC |
Torley HelenDirector
|
GrantCommon Stock | 1,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000139 · wf-form4_155803923677560.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,366 F1 · security: Represents an award of restricted share units. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:39 UTC |
MAIN TIMOTHY LDirector
|
GrantCommon Stock | 1,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000138 · wf-form4_155803917059573.xml · nonDerivative · entry 1 MAIN TIMOTHY L · CIK 0001196744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,057 F1 · security: Represents an award of restricted share units. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:37 UTC |
Gregg Vicky BDirector
|
GrantCommon Stock | 1,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000135 · wf-form4_155803901969649.xml · nonDerivative · entry 1 Gregg Vicky B · CIK 0001510304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,125 F1 · security: Represents an award of restricted share units. F2 · balance_after: The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4 pursuant to the Amended and Restated Deferred Compensation Plan for Directors. F3 · balance_after: The amount includes approximately 137 shares acquired via dividend reinvestment since the date of the last filing on Form 4 pursuant to a dividend reinvestment plan, sponsored by a broker-dealer, that essentially mirrors a dividend reinvestment plan sponsored by the registrant. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:36 UTC |
MORRISON DENISE MDirector
|
GrantCommon Stock | 1,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000134 · wf-form4_155803894745664.xml · nonDerivative · entry 1 MORRISON DENISE M · CIK 0001230166 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,212 F1 · security: Represents an award of restricted share units. F2 · balance_after: The amount includes approximately 6 shares acquired via dividend reinvestment since the date of the last filing on Form 4 pursuant to a dividend reinvestment plan, sponsored by a broker-dealer, that essentially mirrors a dividend reinvestment plan sponsored by the registrant. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:35 UTC |
RING TIMOTHY MDirector
|
GrantCommon Stock | 1,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000133 · wf-form4_155803888989510.xml · nonDerivative · entry 1 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,576 F1 · security: Represents an award of restricted share units. F2 · balance_after: The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4 pursuant to the Amended and Restated Deferred Compensation Plan for Directors. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:33 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 608 | $0.00 Strike: $97.28 | $0.00 |
DisclosureSEC source: 0001022079-19-000124 · wf-form4_155795240817276.xml · derivative · entry 3 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608 Underlying: Common Stock · 608 shares Expires 2029-02-18 F5 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:33 UTC |
Deppe Michael JVP, Corp. Controller & CAO
|
GrantCommon Stock | 52 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000124 · wf-form4_155795240817276.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · VP, Corp. Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,671 F1 · shares: Represents an award of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. F3 · balance_after: The amount includes approximately 59 shares acquired via dividend reinvestment since the date of the last filing on Form 4 pursuant to a dividend reinvestment plan, sponsored by a broker-dealer, that essentially mirrors a dividend reinvestment plan sponsored by the registrant. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 20:29 UTC |
Davis J. E.EVP, General Diagnostics
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 47,574 | $60.68 Strike: $60.68 | $2,886,552.45 |
DisclosureSEC source: 0001022079-19-000120 · wf-form4_155631055894991.xml · derivative · entry 3 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,574 shares Expires 2023-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 7, 2019. F2 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on May 20, 2014, the second on May 20, 2015 and the final on May 20, 2016. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 20:29 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 47,574 | $95.00 | $4,519,530.00 |
DisclosureSEC source: 0001022079-19-000120 · wf-form4_155631055894991.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,534 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 7, 2019. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 20:29 UTC |
Davis J. E.EVP, General Diagnostics
|
Exercise / conversionCommon Stock | 47,574 | $60.68 | $2,886,552.45 |
DisclosureSEC source: 0001022079-19-000120 · wf-form4_155631055894991.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 7, 2019. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:30 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 2,100 | $90.70 | $190,476.30 |
DisclosureSEC source: 0001022079-19-000108 · wf-form4_155492822046893.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,534 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 7, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $90.61 to $90.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:30 UTC |
Davis J. E.EVP, General Diagnostics
|
SaleCommon Stock | 5,900 | $90.15 | $531,855.50 |
DisclosureSEC source: 0001022079-19-000108 · wf-form4_155492822046893.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,634 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 7, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $89.61 to $90.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2019 Filed Apr 8, 2019 20:24 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 60,492 | $71.17 Strike: $71.17 | $4,305,215.64 |
DisclosureSEC source: 0001022079-19-000106 · wf-form4_155475508352754.xml · derivative · entry 5 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,492 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 6, 2019. F6 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 23, 2016, the second on February 23, 2017 and the final on February 23, 2018. Read SEC document |
| April 04, 2019 Filed Apr 8, 2019 20:24 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
SaleCommon Stock | 5,890 | $90.59 | $533,586.88 |
DisclosureSEC source: 0001022079-19-000106 · wf-form4_155475508352754.xml · nonDerivative · entry 3 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,526 F3 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 6, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $90.18 to $91.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2019 Filed Apr 8, 2019 20:24 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
SaleCommon Stock | 60,492 | $90.59 | $5,480,151.76 |
DisclosureSEC source: 0001022079-19-000106 · wf-form4_155475508352754.xml · nonDerivative · entry 2 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,416 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 6, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.08 to $91.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2019 Filed Apr 8, 2019 20:24 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Exercise / conversionCommon Stock | 60,492 | $71.17 | $4,305,215.64 |
DisclosureSEC source: 0001022079-19-000106 · wf-form4_155475508352754.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 6, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:35 UTC |
RING TIMOTHY MDirector
|
GrantPhantom Stock Units · Derivative | 340 | $90.60 Strike: $0.00 | $30,804.00 |
DisclosureSEC source: 0001022079-19-000103 · wf-form4_155432372858523.xml · derivative · entry 1 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,971.681 Underlying: Common Stock · 340 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · balance_after: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:32 UTC |
MORRISON DENISE MDirector
|
GrantPhantom Stock Units · Derivative | 311 | $90.60 Strike: $0.00 | $28,176.60 |
DisclosureSEC source: 0001022079-19-000101 · wf-form4_155432355379454.xml · derivative · entry 1 MORRISON DENISE M · CIK 0001230166 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474 Underlying: Common Stock · 311 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 3,373 | $86.81 | $292,810.13 |
DisclosureSEC source: 0001022079-19-000093 · wf-form4_155182156106751.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,458 F3 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 24, 2018. F4 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 21:26 UTC |
Cunningham EverettSVP, Commercial
|
SaleCommon Stock | 3,892 | $86.81 | $337,864.52 |
DisclosureSEC source: 0001022079-19-000088 · wf-form4_155182119111227.xml · nonDerivative · entry 3 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,311 F3 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 31, 2018. F4 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:34 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 22,698 | $86.86 | $1,971,548.28 |
DisclosureSEC source: 0001022079-19-000094 · wf-form4_155182163358244.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,049 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:34 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
GrantCommon Stock | 38,341 | $86.86 | $3,330,299.26 |
DisclosureSEC source: 0001022079-19-000094 · wf-form4_155182163358244.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,747 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2016, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 3,274 | $86.86 | $284,379.64 |
DisclosureSEC source: 0001022079-19-000093 · wf-form4_155182156106751.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,826 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:32 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantCommon Stock | 6,647 | $86.86 | $577,358.42 |
DisclosureSEC source: 0001022079-19-000093 · wf-form4_155182156106751.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,100 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2016, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:31 UTC |
Klug Robert AVP, Corporate Controller
|
Tax withholdingCommon Stock | 420 | $86.86 | $36,481.20 |
DisclosureSEC source: 0001022079-19-000092 · wf-form4_155182148445877.xml · nonDerivative · entry 2 Klug Robert A · CIK 0001347843 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,261 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. F3 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:31 UTC |
Klug Robert AVP, Corporate Controller
|
GrantCommon Stock | 1,355 | $86.86 | $117,695.30 |
DisclosureSEC source: 0001022079-19-000092 · wf-form4_155182148445877.xml · nonDerivative · entry 1 Klug Robert A · CIK 0001347843 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,648 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2019, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:29 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Tax withholdingCommon Stock | 3,777 | $86.86 | $328,070.22 |
DisclosureSEC source: 0001022079-19-000090 · wf-form4_155182133616795.xml · nonDerivative · entry 2 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,416 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:29 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
GrantCommon Stock | 7,669 | $86.86 | $666,129.34 |
DisclosureSEC source: 0001022079-19-000090 · wf-form4_155182133616795.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,193 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2016, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:30 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 5,288 | $86.86 | $459,315.68 |
DisclosureSEC source: 0001022079-19-000091 · wf-form4_155182141718438.xml · nonDerivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,017 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:30 UTC |
GUINAN MARKExecutive Vice President & CFO
|
GrantCommon Stock | 10,736 | $86.86 | $932,528.96 |
DisclosureSEC source: 0001022079-19-000091 · wf-form4_155182141718438.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,305 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2016, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:27 UTC |
Davis J. E.EVP, General Diagnostics
|
Tax withholdingCommon Stock | 5,839 | $86.86 | $507,175.54 |
DisclosureSEC source: 0001022079-19-000089 · wf-form4_155182126646581.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,534 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. F3 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:27 UTC |
Davis J. E.EVP, General Diagnostics
|
GrantCommon Stock | 10,225 | $86.86 | $888,143.50 |
DisclosureSEC source: 0001022079-19-000089 · wf-form4_155182126646581.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,321 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2016, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:26 UTC |
Cunningham EverettSVP, Commercial
|
Tax withholdingCommon Stock | 3,777 | $86.86 | $328,070.22 |
DisclosureSEC source: 0001022079-19-000088 · wf-form4_155182119111227.xml · nonDerivative · entry 2 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,151 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:26 UTC |
Cunningham EverettSVP, Commercial
|
GrantCommon Stock | 7,669 | $86.86 | $666,129.34 |
DisclosureSEC source: 0001022079-19-000088 · wf-form4_155182119111227.xml · nonDerivative · entry 1 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,928 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 25, 2016, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 22:24 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 1,048 | $86.51 | $90,662.48 |
DisclosureSEC source: 0001022079-19-000078 · wf-form4_155139268485919.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,453 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 24, 2018. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 22:11 UTC |
Cunningham EverettSVP, Commercial
|
SaleCommon Stock | 1,144 | $86.51 | $98,967.44 |
DisclosureSEC source: 0001022079-19-000068 · wf-form4_155139190410701.xml · nonDerivative · entry 3 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,259 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 31, 2018. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:32 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 6,676 | $87.84 | $586,419.84 |
DisclosureSEC source: 0001022079-19-000080 · wf-form4_155139313000306.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,406 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:24 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 364 | $87.06 | $31,689.84 |
DisclosureSEC source: 0001022079-19-000078 · wf-form4_155139268485919.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,501 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 24, 2018. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:24 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 907 | $87.84 | $79,670.88 |
DisclosureSEC source: 0001022079-19-000078 · wf-form4_155139268485919.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,865 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:22 UTC |
Klug Robert AVP, Corporate Controller
|
Tax withholdingCommon Stock | 142 | $87.84 | $12,473.28 |
DisclosureSEC source: 0001022079-19-000076 · wf-form4_155139256118748.xml · nonDerivative · entry 1 Klug Robert A · CIK 0001347843 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,293 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:21 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 1,556 | $87.84 | $136,679.04 |
DisclosureSEC source: 0001022079-19-000074 · wf-form4_155139245730159.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,569 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:15 UTC |
Davis J. E.EVP, General Diagnostics
|
Tax withholdingCommon Stock | 1,432 | $87.84 | $125,786.88 |
DisclosureSEC source: 0001022079-19-000070 · wf-form4_155139211793367.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,096 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:19 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Tax withholdingCommon Stock | 1,066 | $87.84 | $93,637.44 |
DisclosureSEC source: 0001022079-19-000072 · wf-form4_155139235534627.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,524 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:11 UTC |
Cunningham EverettSVP, Commercial
|
SaleCommon Stock | 352 | $87.06 | $30,645.12 |
DisclosureSEC source: 0001022079-19-000068 · wf-form4_155139190410701.xml · nonDerivative · entry 2 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,403 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 31, 2018. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:11 UTC |
Cunningham EverettSVP, Commercial
|
Tax withholdingCommon Stock | 1,112 | $87.84 | $97,678.08 |
DisclosureSEC source: 0001022079-19-000068 · wf-form4_155139190410701.xml · nonDerivative · entry 1 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,755 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:35 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 2,318 | $88.24 | $204,540.32 |
DisclosureSEC source: 0001022079-19-000066 · wf-form4_155131053574827.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,082 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.